Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

被引:10
|
作者
Klein, Florian G. [1 ]
Granier, Charlene [1 ]
Zhao, Yuling [1 ]
Pan, Qi [1 ,3 ]
Tong, Zhichao [1 ,4 ]
Gschwend, Jurgen E. [1 ]
Holm, Per Sonne [1 ,2 ]
Nawroth, Roman [1 ]
机构
[1] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Med Univ Innsbruck, Dept Oral & Maxillofacial Surg, A-6020 Innsbruck, Austria
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Urol, Shanghai 200240, Peoples R China
[4] Hosp Harbin Med Univ, Dept Urol, 23 Youzheng St, Harbin 150086, Peoples R China
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 05期
关键词
bladder cancer; combination therapy; Talazoparib; Olaparib; Palbociclib; Retinoblastoma protein; apoptosis; chorioallantoic membrane model; CELL LUNG-CANCER; CDK4/6; INHIBITORS; DNA-DAMAGE; BREAST-CANCER; POLYMERASE INHIBITORS; CLINICAL DEVELOPMENT; CYCLIN D1; REPAIR; PARP; ACTIVATION;
D O I
10.3390/jpm11050340
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Palbociclib in the treatment of recurrent ovarian cancer
    Lee, Dai Wee
    Ho, Gwo Fuang
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 34
  • [22] Autophagy modulation in bladder cancer development and treatment
    Li, Faping
    Guo, Hui
    Yang, Yuxuan
    Feng, Mingliang
    Liu, Bin
    Ren, Xiang
    Zhou, Honglan
    ONCOLOGY REPORTS, 2019, 42 (05) : 1647 - 1655
  • [23] Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer
    Long, Qilai
    Ma, Ai-Hong
    Zhang, Hongyong
    Cao, Zhixiu
    Xia, Roger
    Lin, Tzu-Yin
    Sonpavde, Guru P.
    White, Ralph de Vere
    Guo, Jianming
    Pan, Chong-Xian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2305 - 2317
  • [24] A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer
    Kong, Chenfan
    Sun, Jianrong
    Hu, Xinzi
    Li, Guangzhi
    Wu, Song
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
    Zhu, Xiuzhi
    Chen, Li
    Huang, Binhao
    Li, Xiaoguang
    Yang, Liu
    Hu, Xin
    Jiang, Yizhou
    Shao, Zhimin
    Wang, Zhonghua
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [26] Anti-cancer effects of ursane triterpenoid as a single agent and in combination with cisplatin in bladder cancer
    Lin, Kai-Wei
    Huang, A-Mei
    Lin, Chi-Chen
    Chang, Chia-Che
    Hsu, Wei-Chi
    Hour, Tzyh-Chyuan
    Pu, Yeong-Shiau
    Lin, Chun-Nan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 : 742 - 751
  • [27] Are androgen receptor agonists a treatment option in bladder cancer?
    De Ieso, Michael L.
    Aldoghachi, Ahmed Faris
    Tilley, Wayne D.
    Dwyer, Amy R.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2025, 245
  • [28] Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells
    Michalska, Marta
    Schultze-Seemann, Susanne
    Kuckuck, Irina
    Katzenwadel, Arndt
    Wolf, Philipp
    ANTICANCER RESEARCH, 2018, 38 (03) : 1369 - 1375
  • [29] CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
    Pan, Qi
    Sathe, Anuja
    Black, Peter C.
    Goebell, Peter J.
    Kamat, Ashish M.
    Schmitz-Draeger, Bernd
    Nawroth, Roman
    BLADDER CANCER, 2017, 3 (02) : 79 - 88
  • [30] Pembrolizumab for the treatment of bladder cancer
    Sundahl, Nora
    Rottey, Sylvie
    De Maeseneer, Daan
    Ost, Piet
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (02) : 107 - 114